Anthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Rating of “Hold” from Analysts
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) have received an average recommendation of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.14.
A number of research firms recently issued reports on ANTH. Zacks Investment Research lowered Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 8th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. Finally, ValuEngine lowered Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
Shares of Anthera Pharmaceuticals (NASDAQ ANTH) traded up 9.49% during mid-day trading on Wednesday, reaching $1.50. The company had a trading volume of 479,435 shares. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $27.36. The stock has a 50 day moving average of $1.41 and a 200-day moving average of $1.19. The company’s market capitalization is $16.36 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. On average, analysts expect that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its stake in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 335,595 shares during the last quarter. UBS Group AG raised its stake in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 33,901 shares during the last quarter. Finally, Sabby Management LLC raised its stake in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 1,665,655 shares during the last quarter. 27.26% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/30/anthera-pharmaceuticals-inc-anth-receives-consensus-rating-of-hold-from-analysts.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.